Technology | Nuclear Imaging | July 16, 2018

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

New features bring high-level clinical capabilities to PET imaging in oncology and neurology

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

July 16, 2018 — At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia, Siemens Healthineers announced U.S. Food and Drug Administration (FDA) clearance of syngo.via VB30 for Molecular Imaging (MI). The latest version of the company’s intelligent imaging software, syngo.via VB30 for MI has new features designed to bring advanced clinical capabilities to positron emission tomography/computed tomography (PET/CT) imaging in oncology and neurology.

syngo.via VB30 for MI automatically calculates a patient’s Deauville score – an internationally recognized scoring system used by oncologists in the initial staging and evaluation of therapeutic response for patients with Hodgkin lymphoma and most types of non-Hodgkin lymphoma. By avoiding the laborious, time-consuming task of manual Deauville score determination, clinicians can save time and increase efficiency.

Also, syngo.via VB30 for MI offers a unique platform for viewing and interpreting parametric PET images. Using dedicated layouts that permit simultaneous visualization of the summed Standard Uptake Values (SUV), the metabolic rate of glucose (MRFDG), and distribution volume images, readers can easily quantify the FDG uptake of these parametric indices.

Additionally, the new platform’s PET/CT and single photon emission computed tomography (SPECT)/CT hybrid VRT (volume-rendering technique) feature enables 3-D visualization of the disease state in a single image. This feature permits user-friendly interpretation of the cancer relative to anatomical landmarks.

Finally, syngo.via VB30 for MI offers improvements for the quantitative analysis of various neurological conditions via either self-created or widely used databases for various disease states. The assessment of striatal activity in the evaluation of Parkinson’s disease, hypometabolic seizure foci in the evaluation of epilepsy, and amyloid plaque burden in the evaluation of dementia can be conducted quantitatively. This ability provides more information to the reading physician to help increase diagnostic confidence.

For more information: www.usa.healthcare.siemens.com

Related Content

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
MaxQ AI Launches Accipio Ax Slice-Level Intracranial Hemorrhage Detection
Technology | Computer-Aided Detection Software | May 21, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August...
Videos | Digital Radiography (DR) | May 20, 2019
This is a quick walk-around video showing the ...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Feature | Artificial Intelligence | May 17, 2019 | Inga Shugalo
With its increasing role in medical imaging,...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Videos | Advanced Visualization | May 16, 2019
This is an example of how virtual reality is being used in neuro-radiology to better evaluate patients using advanced
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...